Aram Mangasarian was appointed CEO of TME Pharma (formerly NOXXON Pharma) in July 2015. He has transformed the company into a lean, publicly quoted company focused on targeting the tumor microenvironment to improve the treatment of solid tumors. Aram brings over twenty years of experience in the biotechnology industry to TME Pharma. Under his leadership, the company has raised close to €65 million.

Prior to joining TME Pharma in May 2010 as Chief Business Officer, Aram served as Vice-President Business Development for Novexel where he concluded a €150 million licensing agreement including a €75 million upfront payment with Forest Laboratories (NYSE:FRX) for North American rights to a beta-lactamase inhibitor now known as avibactam. Aram was a member of the management team that negotiated the subsequent acquisition of Novexel by AstraZeneca (NYSE:AZN) for up to $505 million.

Aram began his career at ExonHit Therapeutics (now Eurobio Scientific, Euronext:ALERS), where he served in a variety of roles eventually heading the business development function as Vice-President. He concluded a number of important agreements for ExonHit, in particular the $30 million strategic alliance with Allergan. Aram was also a non-executive board member at C10 Pharma (Norway) and Isofol Medical (Sweden). Aram received a B.S. from the University of Wisconsin-Madison in biochemistry, molecular biology and English literature, a PhD in Biology from the University of California-San Diego for research carried out at the Salk Institute and an MBA from INSEAD.